ZVRA
ZEVRA THERAPEUTICS, INC. · Healthcare · Market cap $688.3M
Insiders sold $838K net in the last 90 days ·3 sellers, 0 buyers· 2 of 3 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 13, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.5M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Latest filing
Oct 13, 2026
McFarlane Neil F.
ZEVRA THERAPEUTICS, INC. (ZVRA) has 15 SEC Form 4 filings (28 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Oct 13, 2026.
Inside the rolling window, 6 insiders at ZEVRA THERAPEUTICS, INC. reported no open-market purchases and 13 open-market sales totaling $2.5M. The most active filer is Chief Legal & Compliance Thompson Rahsaan with 4 filings. Insiders have net sold $1.3M over the trailing 6 months. The most recent open-market filing is a sale of 20,000 shares by President and CEO McFarlane Neil F., dated Oct 12, 2026, worth $225K.
- Industry:Biotechnology
- CEO:Neil F. McFarlane
- Employees:61
- HQ:Boston, MA, US
- IPO:2015-04-16
| Source | |||||||
|---|---|---|---|---|---|---|---|
McFarlane Neil F.First in 8 months | President and CEO | Sale | 20,000 | $225K | Oct 13 | +11.5% | SEC ↗ |
| Chief Legal & Compliance | Sale | 42,666 | $475K | Aug 17 | +0.5% | SEC ↗ | |
Watton Corey MichaelFirst filing | Director | Sale | 12,300 | $138K | Aug 12 | +1.3% | SEC ↗ |
| Chief Legal & Compliance | Sale | 34,557 | $438K | Jun 23 | -10.8% | SEC ↗ | |
Thompson RahsaanFirst in 3 months | Chief Legal & Compliance | Sale | 1,794 | $20K | May 13 | +4.2% | SEC ↗ |
| President and CEO | Sale | 14,625 | $125K | Feb 10 | +34.6% | SEC ↗ | |
| SVP, Finance & Corp Controller | Sale | 3,000 | $28K | Feb 4 | +29.6% | SEC ↗ | |
| CCO | Sale | 10,500 | $97K | Feb 4 | +29.6% | SEC ↗ | |
Quartel Adrian WFirst filing | Chief Medical Officer | Sale | 4,533 | $40K | Feb 2 | +23.8% | SEC ↗ |
Schafer JoshuaFirst filing | CCO | Sale | 3,375 | $30K | Feb 2 | +23.8% | SEC ↗ |
McFarlane Neil F.First filing | President and CEO | Sale | 91,000 | $853K | Feb 2 | — | SEC ↗ |
Thompson RahsaanFirst filing | Chief Legal & Compliance | Sale | 4,080 | $36K | Feb 2 | — | SEC ↗ |
Sangiovanni Timothy J.First filing | SVP, Finance & Corp Controller | Sale | 1,750 | $15K | Feb 2 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does ZVRA have?
ZEVRA THERAPEUTICS, INC. (ZVRA) has 15 SEC Form 4 filings (28 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Oct 13, 2026.
When was the most recent SEC Form 4 filing for ZVRA?
The most recent Form 4 filing for ZVRA on Tracefour is dated Oct 13, 2026.
Who is the most active insider at ZVRA?
The most active SEC Form 4 filer at ZVRA in the rolling window is Chief Legal & Compliance Thompson Rahsaan, with 4 filings.
What is the net insider flow at ZVRA over the last 6 months?
Over the trailing 180 days, insiders at ZVRA have net sold $1.3M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ZVRA in the current window?
Inside the rolling window, insiders at ZVRA bought $0 and sold $2.5M based on SEC Form 4 filings.
Can I get alerts for ZVRA insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at ZEVRA THERAPEUTICS, INC. (ZVRA). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
ZEVRA THERAPEUTICS, INC. is in the Healthcare sector.